GPR18 Receptor and Full-Spectrum CBD: A Potential Therapeutic Synergy

The endocannabinoid system (ECS) plays a crucial role in maintaining physiological homeostasis, influencing processes such as inflammation, pain modulation, and immune response. While cannabinoid receptors CB1 and CB2 have been well studied, there is increasing interest in lesser-known receptors such as G protein-coupled receptor 18 (GPR18).

GPR18 has been proposed as an "orphan cannabinoid receptor," meaning its classification within the ECS is still under discussion. However, it is known to interact with certain cannabinoids, including tetrahydrocannabinol (Δ⁹-THC) and endogenous lipid signalling molecules like N-arachidonoyl glycine (NAGly). Recent studies suggest that full-spectrum cannabidiol (CBD) products, which contain a range of cannabinoids, terpenes, and flavonoids, may exert therapeutic effects in part through their interactions with GPR18.

This article explores the mechanisms of GPR18 activation, its potential therapeutic benefits, and how full-spectrum CBD may play a role in modulating this receptor for health applications.

Understanding GPR18: A Novel Cannabinoid-Interacting Receptor

What Is GPR18?

GPR18 is a G protein-coupled receptor (GPCR), first identified in 1997. GPCRs are a large family of receptors that mediate numerous physiological responses through their interactions with various ligands. While GPR18 was initially classified as an orphan receptor (meaning its endogenous ligand was unknown), subsequent research has shown that it is activated by several cannabinoids and lipid-based signalling molecules.

Where Is GPR18 Found in the Body?

GPR18 is widely expressed in various tissues, with high concentrations in:

• The immune system (spleen, thymus, leukocytes)
• The central nervous system (CNS) (brainstem, hypothalamus)
• The cardiovascular system (blood vessels, endothelial cells)
• The ocular system (retina, ciliary body)

These expression patterns suggest a role in immune regulation, neuroprotection, vascular function, and eye health.

What Activates GPR18?

GPR18 is activated by several compounds, including:

1. N-Arachidonoyl Glycine (NAGly): An endogenous lipid signalling molecule derived from anandamide, an important endocannabinoid.
2. Δ⁹-THC (Tetrahydrocannabinol): The psychoactive compound in cannabis, which binds to CB1, CB2, and GPR18.
3. Other phytocannabinoids and synthetic cannabinoids: Some evidence suggests that cannabidiol (CBD) and other cannabinoids in full-spectrum extracts can indirectly influence GPR18 signalling.

The Role of Full-Spectrum CBD in GPR18 Activation

What Is Full-Spectrum CBD?

Full-spectrum CBD products contain a range of naturally occurring cannabinoids, terpenes, flavonoids, and other plant compounds found in Cannabis sativa. Unlike CBD isolate, which contains only cannabidiol, full-spectrum extracts retain trace amounts of Δ⁹-THC, cannabigerol (CBG), cannabichromene (CBC), and other minor cannabinoids that may contribute to the "entourage effect."

The entourage effect suggests that the various compounds in cannabis work synergistically to enhance therapeutic benefits compared to isolated CBD alone.

How Does Full-Spectrum CBD Affect GPR18?

1. Direct and Indirect Activation: Δ⁹-THC, present in trace amounts in full-spectrum extracts, is a full agonist at GPR18, meaning it directly binds to and activates the receptor. Some researchers believe CBD may modulate GPR18 activity indirectly by affecting its interaction with endogenous cannabinoids like NAGly.
2. Anti-Inflammatory Effects: Full-spectrum CBD products have been shown to reduce inflammation, which aligns with research suggesting that GPR18 activation plays a role in immune cell migration and inflammatory responses.
3. Potential Neuroprotective Benefits: CBD is known for its neuroprotective properties, and GPR18 activation in the CNS may help protect against neurodegenerative diseases by modulating inflammation and oxidative stress.

Therapeutic Potential of GPR18 Activation

1. Immune Modulation and Inflammation Control

GPR18 is expressed in immune cells, including T-cells and macrophages, and is involved in regulating immune responses. Activation of this receptor has been linked to:

• Reduced pro-inflammatory cytokine production
• Regulation of white blood cell migration
• Modulation of autoimmune responses

Since full-spectrum CBD products contain cannabinoids that influence GPR18 activity, they may be beneficial in conditions involving chronic inflammation and immune dysregulation, such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease (IBD).

2. Pain Management and Analgesia

Studies suggest that GPR18 plays a role in pain perception. Activation of this receptor has been linked to:

• Reduction in neuropathic pain
• Lower inflammation-related pain sensitivity
• Potential analgesic effects in inflammatory conditions

Full-spectrum CBD has shown promise in pain relief, and its interaction with GPR18 may contribute to its analgesic effects.

3. Ocular Health and Glaucoma Treatment

GPR18 is highly expressed in the eye, particularly in the ciliary body and retina, where it plays a role in intraocular pressure (IOP) regulation. Research suggests that activating GPR18:

• Reduces intraocular pressure (IOP)
• Enhances neuroprotection in retinal cells
• May be beneficial for glaucoma patients

Cannabinoids in full-spectrum CBD, particularly Δ⁹-THC and minor cannabinoids, may help regulate GPR18 signalling in the eye.

4. Cardiovascular and Metabolic Health

Recent research suggests that GPR18 is involved in blood pressure regulation, lipid metabolism, and vascular health. Some potential benefits include:

• Lowering blood pressure by modulating vascular tone
• Reducing cholesterol and triglyceride levels
• Enhancing endothelial function and reducing inflammation in blood vessels

Full-spectrum CBD’s cardiovascular benefits may be partially attributed to GPR18 activation, along with its general anti-inflammatory and antioxidant effects.

Conclusion

The GPR18 receptor is an emerging target in cannabinoid research, with promising implications for immune regulation, pain management, ocular health, and cardiovascular function.

Full-spectrum CBD products, which contain a range of cannabinoids, terpenes, and flavonoids, may exert some of their therapeutic effects through interactions with GPR18. While Δ⁹-THC appears to be a direct activator, CBD and other minor cannabinoids may modulate GPR18 activity indirectly, contributing to anti-inflammatory, neuroprotective, and analgesic properties.

As research on GPR18 continues, its role in cannabinoid pharmacology may pave the way for new therapies targeting inflammation, pain, metabolic disorders, and ocular diseases.

References

1. Alexander, S. P. H., et al. (2011). "Cannabinoid pharmacology: The first 66 years." British Journal of Pharmacology, 163(7), 1479-1494. https://bpspubs.onlinelibrary.wiley.com
2. Kohno, M., et al. (2006). "Identification of N-arachidonoyl glycine as the endogenous ligand for GPR18." Biochemical and Biophysical Research Communications, 347(3), 827-832. https://www.sciencedirect.com
3. McHugh, D., et al. (2012). "GPR18 in microglia mediates cannabinoid-induced migration of microglial cells." Journal of Neuroscience, 32(5), 1408-1423. https://www.jneurosci.org
4. Console-Bram, L., et al. (2014). "Cannabinoid receptors and their novel signaling mechanisms." Neuropharmacology, 76, 26-37. https://www.sciencedirect.com